Kate Haviland has served as a member of our board of directors since September 2023. Ms. Haviland previously served as the President and Chief Executive Officer and a member of the board of directors of Blueprint Medicines Corporation, or Blueprint, a publicly traded biopharmaceutical company, from April 2022 until its acquisition by Sanofi in July 2025. Ms. Haviland was the Chief Operating Officer at Blueprint from January 2019 to April 2022 and the Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, and as head of commercial development at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a biopharmaceutical and drug development company, from June 2012 to April 2014. Ms. Haviland currently serves on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a biopharmaceutical company, as well as a number of private companies. Ms. Haviland holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. We believe Ms. Haviland is qualified to serve on our board of directors because of her experience as an executive and director of publicly traded life sciences companies.